US equities
|
NVDA
$239.60
▲+2.41%
SPCX
$169.72
▲+6.77%
MU
$1,062.31
▼-1.17%
TSLA
$379.92
▲+2.52%
SNDK
$1,701.52
▼-1.07%
MSFT
$527.94
▲+2.01%
INTC
$116.16
▼-2.66%
META
$743.10
▲+2.06%
NVDA
$239.60
▲+2.41%
SPCX
$169.72
▲+6.77%
MU
$1,062.31
▼-1.17%
TSLA
$379.92
▲+2.52%
SNDK
$1,701.52
▼-1.07%
MSFT
$527.94
▲+2.01%
INTC
$116.16
▼-2.66%
META
$743.10
▲+2.06%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Halberd Corp
(OP:
HALB
)
0.0015
-0.0005 (-25.00%)
Delayed Quote
Updated: 3:24 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halberd Corp
< Previous
1
2
3
4
5
Next >
Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
February 22, 2022
JACKSON CENTER, PA / ACCESSWIRE / February 22, 2022 / Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination...
From
Halberd Corporation
Via
AccessWire
Halberd Eliminates 100% of Tau Protein From CSF - The 9th of 10 Target Neurodegenerative Disease Antigens
February 08, 2022
Tau buildup in the brain is linked to Alzheimer's and other neurodegenerative diseases. JACKSON CENTER, PA / ACCESSWIRE / February 8, 2022 / Halberd Corporation (OTC PINK:HALB) has demonstrated the...
From
Halberd Corporation
Via
AccessWire
Halberd Achieves Landmark Selective Elimination of Tau From an Antigen Mixture
February 01, 2022
Tau has been shown to be important in the development of Alzheimer's Disease. Eradication of Tau accomplished without reducing levels of non-target cytokine. JACKSON CENTER, PA / ACCESSWIRE / February...
From
Halberd Corporation
Via
AccessWire
Halberd CEO Letter: 2021 Year-End & 2022 Outlook
January 25, 2022
JACKSON CENTER, PA / ACCESSWIRE / January 25, 2022 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB) First of all I want to wish all of our shareholders and constituents a Very...
From
Halberd Corporation
Via
AccessWire
Halberd, Inc. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases
January 13, 2022
JACKSON CENTER, PA / ACCESSWIRE / January 13, 2022 / Halberd, Inc. (OTC PINK:HALB) ("HALB" or the "Company"), an innovative biotech company focused on developing treatments for difficult-to-cure...
From
Halberd Corporation
Via
AccessWire
Halberd Corporation Now an Official US Government Contractor
January 05, 2022
Halberd to bid on Additional Federal Contracts with the Federal Government JACKSON CENTER, PA / ACCESSWIRE / January 5, 2022 / Halberd Corporation (OTC PINK:HALB) is now registered with the Federal...
From
Halberd Corporation
Via
AccessWire
Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases
December 20, 2021
Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid JACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation (OTC Pink:HALB) has been able to successfully eliminate...
From
Halberd Corporation
Via
AccessWire
Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases
December 15, 2021
JACKSON CENTER, PA / ACCESSWIRE / December 15, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in...
From
Halberd Corporation
Via
AccessWire
Halberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
December 13, 2021
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE
December 06, 2021
JACKSON CENTER, PA / ACCESSWIRE / December 6, 2021 / Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Halberd Successfully Eradicates TNF-a, a Major Contributing Factor to Alzheimer’s Disease
November 22, 2021
JACKSON CENTER, PA / ACCESSWIRE / November 22, 2021 / Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF)...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves
November 08, 2021
JACKSON CENTER, PA / ACCESSWIRE / November 8, 2021 / Halberd Corporation (OTC PINK:HALB) filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease
November 01, 2021
Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer's Disease. JACKSON CENTER, PA / ACCESSWIRE / November 1, 2021 / Halberd Corporation (OTC...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Files Provisional Patent on Breakthrough Obesity Treatment
October 25, 2021
JACKSON CENTER, PA / ACCESSWIRE / October 25, 2021 / Halberd Corporation (OTC PINK:HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd's PTSD/Alzheimer's R&D Reveals Link to Potential Obesity Cure
October 20, 2021
JACKSON CENTER, PA / ACCESSWIRE / October 20, 2021 / Halberd Corporation's (OTC PINK:HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer's Disease, and other neurodegenerative...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd and GTX Corp. Sign Scientific Collaboration and Reseller Agreement
October 12, 2021
GTX and Halberd will begin collaborating on developing and testing treatments for Alzheimer's Disease/PTSD and other neurological diseases and GTX will begin marketing Halberd's VitaShieldMaxTM Immune...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Corporation CEO Letter
October 07, 2021
JACKSON CENTER, PA / ACCESSWIRE / October 7, 2021 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB) This past quarter, Halberd has made some very significant and unparalleled...
From
Halberd Corporation
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Halberd's VITASHIELDMAX(TM) Immunity Support Product Available on Amazon
October 05, 2021
JACKSON CENTER, PA / ACCESSWIRE / October 5, 2021 / Halberd Corporation (OTC PINK:HALB) announced that its nutraceutical immune support product, VitaShieldMaxTM, is now available through Amazon, in...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd and heliosDX of RushNet Enter Scientific Collaboration Agreement
September 22, 2021
Agreement To Advance Healthcare Diagnostic Technologies JACKSON CENTER, PA / ACCESSWIRE / September 22, 2021 / Halberd Corp. (OTC PINK:HALB) and heliosDx, a wholly owned company of RushNet, Inc. (OTC...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd's Treatment Eradicates Primary Building Block of Alzheimer’s Disease
September 13, 2021
JACKSON CENTER, PA / ACCESSWIRE / September 13, 2021 / Halberd Corporation (OTC PINK:HALB) has successfully eradicated the primary building block of neurofibrillary tangles of Alzheimer's Disease from...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Corporation Appoints Anthony Mirabelli Vice-President, Mergers & Acquisitions
September 08, 2021
JACKSON CENTER, PA / ACCESSWIRE / September 8, 2021 / Halberd Corporation (OTC PINK:HALB) announced the appointment of Anthony Mirabelli to the position of Vice-President, Mergers & Acquisitions....
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Corporation Alzheimer's Disease Treatment Tests Yield Outstanding Results
August 30, 2021
JACKSON CENTER, PA / ACCESSWIRE / August 30, 2021 / Halberd Corp. (OTC PINK:HALB) provided an update on its Alzheimer's Disease eradication experimentation being conducted at Youngstown State...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Receives Patent for Treatment of Cockayne Syndrome - May Provide Pathway to Slow Aging
August 25, 2021
JACKSON CENTER, PA / ACCESSWIRE / August 25, 2021 / Halberd Corporation (OTC PINK:HALB) received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office,...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Files Provisional Patent Application - Furthering Efforts on Alzheimer's Disease
August 23, 2021
JACKSON CENTER, PA / ACCESSWIRE / August 23, 2021 / Halberd Corp. (OTC PINK:HALB) announced filing a U. S. joint provisional patent application, "Treating Alzheimer's Disease Utilizing Extracorporeal...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Halberd Corp. VITA-SHIELD-MAX(TM) Available - Buy Now!
August 18, 2021
JACKSON CENTER, PA / ACCESSWIRE / August 18, 2021 / Halberd Corporation's (OTC PINK:HALB) Nutraceutical product, Vita-Shield-MaxTM is now available on www.vitashieldmax.com. Vita-Shield-MaxTM is a...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd’s Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN
August 16, 2021
JACKSON CENTER, PA / ACCESSWIRE / August 16, 2021 / Halberd Corporation's (OTC PINK:HALB) research at Youngstown State University (YSU) caught the attention of Youngstown, OH TV news station, WKBN, a...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Corporation Adds Blood-Borne Disease Treatment Capability With Addition Of Noted Nephrologist
August 11, 2021
JACKSON CENTER, PA / ACCESSWIRE / August 11, 2021 / Halberd Corporation (OTC PINK:HALB) today confirmed the addition of Dr. Ned Kronfol as a member of its Scientific Advisory Board. Dr. Kronfol is...
From
Halberd Corporation
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Halberd Corporation's VITA-SHIELD-MAX(TM) Immunity Support Product Shipped
August 09, 2021
JACKSON CENTER, PA / ACCESSWIRE / August 9, 2021 / Halberd Corporation (OTC PINK:HALB) reports Vita-Shield-MaxTM, has been shipped! With Covid-19 cases back on the rise fueled by the Delta Variant,...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept - "Never Before Accomplished"
July 28, 2021
A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer's Disease/PTSD/CTE JACKSON CENTER, PA / ACCESSWIRE / July 28, 2021 / Halberd Corporation (OTC...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy
July 22, 2021
JACKSON CENTER, PA / ACCESSWIRE / July 22, 2021 / Halberd Corporation (OTC PINK:HALB) confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer's Disease (AD) antibodies, Tau...
From
Halberd Corporation
Via
AccessWire
Topics
Intellectual Property
< Previous
1
2
3
4
5
Next >
